CN104474472A - 具有降三高作用的苦丁茶含片及其生产方法 - Google Patents
具有降三高作用的苦丁茶含片及其生产方法 Download PDFInfo
- Publication number
- CN104474472A CN104474472A CN201410722040.7A CN201410722040A CN104474472A CN 104474472 A CN104474472 A CN 104474472A CN 201410722040 A CN201410722040 A CN 201410722040A CN 104474472 A CN104474472 A CN 104474472A
- Authority
- CN
- China
- Prior art keywords
- parts
- high blood
- extracting solution
- hour
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 210000004369 blood Anatomy 0.000 title abstract description 44
- 239000008280 blood Substances 0.000 title abstract description 44
- 206010020772 Hypertension Diseases 0.000 title abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 8
- 239000008103 glucose Substances 0.000 title abstract description 8
- 229940046011 buccal tablet Drugs 0.000 title abstract description 7
- 239000006189 buccal tablet Substances 0.000 title abstract description 7
- 150000002632 lipids Chemical class 0.000 title abstract description 5
- 235000003332 Ilex aquifolium Nutrition 0.000 title abstract 5
- 235000002296 Ilex sandwicensis Nutrition 0.000 title abstract 5
- 235000002294 Ilex volkensiana Nutrition 0.000 title abstract 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 24
- 239000000945 filler Substances 0.000 claims abstract description 21
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 18
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 239000012530 fluid Substances 0.000 claims description 36
- 238000001802 infusion Methods 0.000 claims description 36
- 239000007937 lozenge Substances 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 24
- 235000008597 Diospyros kaki Nutrition 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 20
- 244000025254 Cannabis sativa Species 0.000 claims description 18
- 241000124879 Grus leucogeranus Species 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 12
- 239000007779 soft material Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000004368 Modified starch Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 9
- 241000209035 Ilex Species 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 240000001829 Catharanthus roseus Species 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 235000011511 Diospyros Nutrition 0.000 abstract 1
- 240000002396 Rhinacanthus nasutus Species 0.000 abstract 1
- 244000185386 Thladiantha grosvenorii Species 0.000 abstract 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 73
- 241001122767 Theaceae Species 0.000 description 33
- 230000036772 blood pressure Effects 0.000 description 19
- 206010011224 Cough Diseases 0.000 description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 7
- 230000035922 thirst Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000219104 Cucurbitaceae Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 201000008197 Laryngitis Diseases 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000015177 Saccharina japonica Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 241001278836 Agrimonia pilosa Species 0.000 description 1
- 235000000641 Agrimonia pilosa Nutrition 0.000 description 1
- 241000199899 Alariaceae Species 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 240000009005 Calendula arvensis Species 0.000 description 1
- 235000007864 Calendula arvensis Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000004360 Dioscorea zingiberensis Nutrition 0.000 description 1
- 241001678283 Dioscorea zingiberensis Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 241000792913 Ebenaceae Species 0.000 description 1
- 241000946389 Ecklonia kurome Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 244000078118 Ilex latifolia Species 0.000 description 1
- 235000008706 Ilex latifolia Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001633680 Polygonatum odoratum Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001409305 Siraitia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000006231 esophageal tuberculosis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000009982 suxiao jiuxinwan Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种具有降三高作用的苦丁茶含片及其生产方法,其特征在于:由下列重量份数的原料制成:苦丁茶90-100份、罗汉果20-30份、玉竹8-12份、白鹤草8-12份、柿子叶4-8份、姜黄3-5份、昆布3-5份、长春花1-2份、烟酸1-2份、薄荷脑1-2份、填充剂50-70份、润滑剂10-15份。本发明具有降三高作用的苦丁茶含片具有降血糖、降血脂、降血压,还具有清热解毒、健脾安神、减肥、抑癌防癌等特点。
Description
技术领域
本发明属于中草药制剂技术领域,具体涉及一种具有降血压、降血脂、降血糖作用的苦丁茶含片及其生产方法。
背景技术
随着几十年来经济水平的提高和物质条件的改善,人们的膳食结构也发生了潜移默化的改变。现代人的饮食已经由过去的温饱型向营养热量过剩型转化,随之而来的是人们在健康方面为此所付出的巨大代价。过去许多只能在老年人身上才能看到的疾病,如高血压、高血糖、高血脂等正在快速地向中青年群体转移。为了控制和纠正体内出现的这些偏差,有许多人都不得不依赖于各种药物来维持健康指标的正常值。为了满足这种需要,目前的医药生产厂家已经开发许许多的降血压、降血糖和降血脂的化学药物,这些药物虽然有不少确实对人体的指标恢复确实起到了明显的作用,但是随之而来的许多副作用却又给人们带来了不少新的烦恼。尤其是有许多人,在他们身上同时存在着高血压、高血脂和高血糖症状,对于这些人的治疗难度和在治疗中的烦恼就更多了。近年来许多人都特希望能够借助于传统中药来解除病痛。目前已有的中药能够分别治疗高血压、高血糖、高血脂的药物虽然很多,但是能够同时治疗这三种疾病的药物并不太多。
现代医学研究表明,苦丁茶中含有苦丁皂甙、氨基酸、维生素 C、多酚类、黄酮类、咖啡碱、蛋白质等200多种成分,具有清热消暑、明目益智、生津止渴、利尿强心、润喉止咳、降血脂、降血压、降血糖、减肥、抑癌防癌、抗衰老、活血脉等多种功效。是茶叶保健食品的研究热点之一,长期以来茶叶的食用方式多以泡饮为主,形式较为单一,且利用率不够高,与传统的袋泡或散泡相比,茶叶口含片携带方便,使用简单,能最大限度利用其有效成分,满足现代人营养保健、 简便快捷的消费需求,但由于茶味太淡、口感不佳等问题,导致市场的认可度不高,无法满足市场需求。因此,研制一种具有降血糖、降血压、降血脂的苦丁茶含片是非常必要的。
发明内容
本发明的目的是针对上述现有技术不足而提供一种无毒副作用,具有降血糖、降血脂、降血压,还具有清热解毒、健脾安神、减肥、抑癌防癌作用的苦丁茶含片及其生产方法。
本发明是采用以下技术方案实现的:
本发明具有降三高作用的苦丁茶含片,由下列重量份数的原料制成:
苦丁茶90-100份、罗汉果20-30份、玉竹8-12份、白鹤草8-12份、柿子叶4-8份、姜黄3-5份、昆布3-5份、长春花1-2份、烟酸1-2份、薄荷脑1-2份、填充剂50-70份、润滑剂10-15份。
以上所述的具有降三高作用的苦丁茶含片,由下列重量份数的原料制成:苦丁茶95份、罗汉果25份、玉竹10份、白鹤草10份、柿子叶6份、姜黄4份、昆布4份、长春花1份、烟酸1份、薄荷脑1份、填充剂60份、润滑剂12份。
本发明由苦丁茶95份、罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花等中药药材组成,再结合烟酸和薄荷脑复配,具有降血糖、降血脂、降血压,还具有清热解毒、健脾安神、减肥、抑癌防癌的作用。
以上所述的具有降三高作用的苦丁茶含片中药配方的各药有效成份分析:
苦丁茶,【别名】大叶冬青;【拉丁文】Ilex latifolia Thunb,葫芦科,为冬青科植物大叶冬青(学名:Folium llicis Latifoliae)的叶,生于山坡、竹林、灌木丛中。分布于长江下游各省及福建。苦丁茶俗称茶丁、富丁茶、皋卢茶,是中国一种传统的纯天然保健饮料佳品,素有“保健茶”、“美容茶”、“减肥茶”、“降压茶”、“益寿茶”等美称。【性味】甘、苦、寒;【功能主治】具有清热消暑、明目益智、生津止渴、利尿强心、润喉止咳、降血脂、降血压、降血糖、减肥、抑癌防癌、抗衰老、活血脉等多种功效。①《本草纲目》:苦丁茶具有散风热、清头目、生津止渴、消食提神、消炎解毒、降压降脂等药理功能。②《本草再新》:消食化痰,除烦止渴,利二便,去油腻。③《四川中药志》:能清热散风,除烦解渴。治头痛、齿痛、耳鸣、目赤及食滞有痰。
罗汉果,【别名】拉汗果、假苦瓜、光果木鳖、金不换、罗汉表、裸龟巴;【拉丁文】Siraitia grosuenorii,葫芦科,生长在海拔300~1400米亚热带山坡林下、河边湿润地段或灌木丛林中,主要产于广西壮族自治区桂林市永福县龙江乡、龙胜和百寿等镇,【性味】味甘性凉;【功能主治】清咽利肺、止咳化痰、滑肠排毒。①《岭南采药录》:理痰火咳嗽,和猪精肉煎汤服之。②《广西中药志》:止咳清热,凉血润肠。治咳嗽,血燥胃热便秘等。果实营养价值很高,含丰富的维生素C(每100克鲜果中含400毫克~500毫克)以及糖甙、果糖、葡萄糖、蛋白质、脂类等。
玉竹,【别名】葳蕤、女萎、节地、玉术、竹节黄、竹七根,拉丁文名:Polygonatum odoratum (Mill.)Druce. 百合科多年生草本植物玉竹的根茎。分布于东北、华北、华东及湖北、湖南、广东,浙江,内蒙,安徽等地。【性味】甘、平,【功能主治】热病阴伤、咳嗽烦渴、虚劳发热、小便频数、消谷易饥,还具有降血脂、降血压,滋养、镇静及强心的作用。①《滇南本草》:补气血,补中健脾。②《广西中药志》:养阴清肺润燥。治阴虚,多汗,燥咳,肺痿。
白鹤草,【别名】仙鹤草,白鹤灵芝,灵芝草;【拉丁文】Agrimonia pilosa Ldb. 为蔷薇科植物龙芽草的干燥地上全草,原产中国大陆云南,华南之广东、广西山区一带,东南亚地区及印度等地。性味功效:苦、涩、平。【功能主治】肺热、热咳、喘咳、肺结核、食道结核、鼻病、支气管炎、喉炎、肝病、肾脏病、糖尿病等症。
柿子叶,【别名】柿叶;【拉丁文】Diospyros kaki L.f. Extract,柿子叶为柿科乔木植物柿的叶;我国南北都广泛分布的水果。【性味】味苦,性寒,无毒;【功能主治】具有止渴生津、消肺气胀、降低血压、软化血管、清血和消炎的作用。①《本草再新》:柿子叶治咳嗽吐血,止渴生津。②《分类草药性》:柿子叶治咳嗽气喘,消肺气胀。
姜黄,【别名】郁金、宝鼎香、毫命、黄姜;【拉丁文】Curcuma longa L. 多年生草本植物;分布于福建、广东、广西、云南、西藏等地。【性味】味辛苦,大寒,无毒,【功能主治】破血,行气,通经,止痛,降血脂。①《唐本草》:主心腹结积,疰忤,下气,破血,除风热,消痈肿。②《本草正》:除心腹气结气胀,冷气食积疼痛。③《现代实用中药》:为芳香健胃药,有利胆道及肝脏之消毒作用。
昆布,【别名】纶布、海昆布;【拉丁文】Laminaria japonica Aiesch,为海带科植物海带(Laminaria japonica Aresch)或翅藻科植物昆布(鹅掌菜)(Ecklonia kurome Okam)的干燥叶状体。分别于辽东、山东、浙江、福建等地。【性味】咸,寒,【功能主治】具有清热解毒,消肿散结,利尿通淋的功效;主治热毒、痈肿、疮疡、内痈、目赤肿痛、湿热等疾。①《中华人民共和国药典》: 1.对甲状腺的作用:具作用是由于所含的碘、碘化物引起的。2.降压作用:海带氨酸(Laminine)具有降压作用,海带氨酸单枸橼酸盐对麻醉兔静脉注射,可使血压短暂下降。3.降血糖作用:昆布中所含褐藻淀粉30ml/kg灌胃对正常小鼠有明显的降血糖作用,剂量达100mg/kg时,7小时后血糖降低49%。4.降血脂和抗凝作用:海带多糖多次灌胃,能明显地抑制高血脂鸡血清总胆固醇、甘油三酯的含量上升,并能减少鸡主动脉内膜粥样斑块的形成及发展。
长春花,【别名】金盏草、四时春、日日新、雁头红、三万花;【拉丁文】Catharanthus roseus (L.)G. Don,夹竹桃科;广东、广西、云南等省(自治区)栽培较为普遍。。【性味】甘,微苦,寒,【功能主治】具有凉血降压,镇静安神。用于高血压、火烫伤、恶性淋巴瘤、绒毛膜上皮癌、单核细胞性白血病。。①广州部队《常用中草药手册》:镇静安神,平肝降压。治高血压。②《广西药植名录》:治白血病,肺癌,绒毛膜上皮癌,淋巴肿瘤。③《常用中草药彩色图谱》:治疗何杰金氏病、恶性肿瘤。
烟酸也称作维生素B3,或维生素PP,分子式:C6H5NO2,耐热,能升华,具有强化降脂的作用。它是人体必需的13种维生素之一,是一种水溶性维生素,属于维生素B族。烟酸在人体内转化为烟酰胺,烟酰胺是辅酶Ⅰ和辅酶Ⅱ的组成部分,参与体内脂质代谢,组织呼吸的氧化过程和糖类无氧分解的过程。
薄荷脑是一种化学药剂,是由薄荷的叶和茎中所提取,白色晶体,分子式C10H20O,为薄荷和欧薄荷精油中的主要成分。在医药上用作刺激药,作用于皮肤或粘膜,有清凉止痒作用;内服可作为驱风药,用于头痛及鼻;咽;喉炎症等。其酯用于香料和药物。
上述各组份药物制成本发明具有降三高作用的苦丁茶含片的生产方法,包括以下步骤:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用。
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
以上所述的乙醇沉淀是将质量分数为80-90%的乙醇加入浓缩液中,边搅拌边缓慢添加,调至浓缩液中醇含量为40-70%时密闭2-4小时再过滤。
以上所述的填充剂为糊精、微晶纤维素、变性淀粉、预胶化淀粉、木糖醇,羧甲基淀粉钠中的一种或几种。
以上所述的湿滑剂为硬脂酸盐、滑石粉、氢化物植物油、聚乙二醇中的一种或几种。
具有降三高作用的苦丁茶含片,根据不同情况和加工厂的条件,还可以制成苦丁茶液体饮料、苦丁袋泡茶、苦丁茶颗粒冲剂及其它制品。
本发明的有益效果是:
1、本发明清咽利喉苦丁茶含片采用产自广西大新县苦丁茶、广西桂林的罗汉果等草本植物精制而成,苦丁茶、罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花全部是药食两用的原料,无副作用,无不良气味,口感清新、自然、爽口。
2、本发明苦丁茶含片对治疗高血压、脑动脉硬化、降血脂、降血糖、降低胆固醇、肥胖症、防治糖尿病具有快速、特效;还具有清热解毒、健脾安神、减肥、抑癌防癌作用;彻解除了三高患者病魔之苦,并使使健康人群得到了有效保健,无任何毒副作用,安全可靠。
3、本发明苦丁茶含片加入烟酸、薄荷脑和罗汉果,使苦丁茶含片口感微甜、清爽,消除了苦丁茶的苦味,更受三高人群的喜爱,也合适任何人群服用。
4、本发明添加入罗汉果,现代医药学研究发现,罗汉果含有丰富的糖甙,这种糖甙的甜度是蔗糖甜度的300倍,不产生热量,是饮料、糖果行业的名贵原料,是蔗糖的最佳替代品,不升高血糖,并且具有降血糖作用,可以用来辅助治疗糖尿病;所以是糖尿病病人的食疗佳品。
5、本发明的原料成分及重量份经过长期的试验和反复比较和使用,得出了科学配伍,互相为用、密不可分,具有很好的治疗效果。
具体实施方式
实施例1:
(一)原料及重量:
苦丁茶90份、罗汉果20份、玉竹8份、白鹤草8份、柿子叶4份、姜黄3份、昆布3份、长春花1份、烟酸1份、薄荷脑1份、填充剂50份、润滑剂10份。
(二)生产方法:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用。
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
以上所述的填充剂为糊精;以上所述的湿滑剂为硬脂酸盐。
实施例2:
(一)原料及重量:
苦丁茶95份、罗汉果25份、玉竹10份、白鹤草10份、柿子叶6份、姜黄4份、昆布4份、长春花1份、烟酸1份、薄荷脑1份、填充剂60份、润滑剂12份。
(二)生产方法:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用。
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
以上所述的填充剂为木糖醇;以上所述的湿滑剂为滑石粉。
实施例3:
(一)原料及重量:
苦丁茶98份、罗汉果28份、玉竹11份、白鹤草11份、柿子叶7份、姜黄4份、昆布4份、长春花2份、烟酸2份、薄荷脑2份、填充剂65份、润滑剂14份。
(二)生产方法:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用。
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
以上所述的填充剂为羧甲基淀粉钠;以上所述的湿滑剂为氢化物植物油。
实施例4:
(一)原料及重量:
苦丁茶100份、罗汉果30份、玉竹12份、白鹤草12份、柿子叶8份、姜黄5份、昆布5份、长春花2份、烟酸2份、薄荷脑2份、填充剂70份、润滑剂15份。
(二)生产方法:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用。
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
以上所述的填充剂为糊精、微晶纤维素、变性淀粉和木糖醇;以上所述的湿滑剂为氢化物植物油和聚乙二醇。
应用实施例
本发明的具有降三高作用的苦丁茶含片于2012年研究并试制出来的产品给部分人群进行服用,志愿者30名,其中有糖尿病、高血压、高血脂等症状。每天服用4-8片,服用3-5天后,三项指标全部有明显下降的有27人,结果患者服用后有效率达到90%以上,除了3名症状较严重者需要到医院治疗以外,27名均不用去医院,也不服用西药。对于患有严重糖尿病的高血压、高血脂患者,服用本发明药物的同时配合其它降糖药物治疗,血压、血脂明显下降,其它降糖药物的用量也可以减少10%至30%,糖化血红蛋白值也明显下降,提示血糖已趋于平稳。
典型病例
1、彭某某,女,45岁,2013年11月确诊为高血脂兼冠心病,每天服用丹参片、脑血通、速效救心丸等心脑血管疾病药,不见好转;经服用本发明的苦丁茶含片,每天服用4-8片,2天后症状大为减轻,服用一个星期后,血压平稳,一个月后医院检查, 血脂指数基本正常。
2、秦某某,男,55岁,某企业高管,患有糖尿病,经北京、上海等大医院治疗后,效果不佳,经常注射胰岛素和超强抗氧化剂治疗,经服用本发明的苦丁茶含片,每天服用4-8片,5天后血压、血糖下降,连续服用三个疗程后血糖指数基本正常,无需注射胰岛素治疗。
3、谭某,男,62岁,因经常抽烟饮酒过量,患有高血压、高血脂及冠心病多年,经服用本发明的苦丁茶含片,每天服用4-8片,一个疗程后,血压、血脂平稳,30天后血压、血脂恢复正常,平时经常服用,直到至今也没有复发。
4、张某某,女,52岁,教师,换糖尿病多年,每天起夜7-8次,经服用本发明的苦丁茶含片一个星期后,每天起夜次数减少为2-3次。
5、韦某,72岁,患有高血压、高血脂以及失眠等病症多年,坚持服用本发明的苦丁茶含片,每天3次,每次含用2片,一个星期后睡眠正常,高血压和高血脂指标下降,继续服用1个月后,血压、血脂恢复正常。
Claims (6)
1.一种具有降三高作用的苦丁茶含片,其特征在于:由下列重量份数的原料制成:苦丁茶90-100份、罗汉果20-30份、玉竹8-12份、白鹤草8-12份、柿子叶4-8份、姜黄3-5份、昆布3-5份、长春花1-2份、烟酸1-2份、薄荷脑1-2份、填充剂50-70份、润滑剂10-15份。
2.根据权利要求1所述的具有降三高作用的苦丁茶含片,其特征在于:由下列重量份数的原料制成:苦丁茶95份、罗汉果25份、玉竹10份、白鹤草10份、柿子叶6份、姜黄4份、昆布4份、长春花1份、烟酸1份、薄荷脑1份、填充剂60份、润滑剂12份。
3. 一种具有降三高作用的苦丁茶含片的生产方法,其特征在于:包括苦丁茶有效成分的提取和罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花有效成分的提取,具体步骤如下:
(1)按重量份数将苦丁茶粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液A;
(2)将步骤1中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液B;
(3)将步骤2中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液A和提取液B混在一起搅拌,加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(4)按重量份数将罗汉果、玉竹、白鹤草、柿子叶、姜黄、昆布、长春花粉碎后倒入提取罐,加入水量为药物总重量的10倍,加热至100℃熬煮1.5-2小时,待药液温度降至35℃-50℃时,经120目筛网过滤,得到提取液C;
(5)将步骤4中过滤后的药渣加入水量为药物总重量的5倍,加热至100℃熬煮1小时,待药液温度降至35-50℃时,经120目筛网过滤,得到提取液D;
(6)将步骤5中过滤后的药渣加入水量为药物总重量的3倍,加热至100℃熬煮0.5小时,待药液温度降至35-50℃时,经120目筛网过滤,再把提取液C和提取液D混合,先加入烟酸和薄荷脑搅拌均匀,再加入提取液重量5倍的乙醇进行沉淀,乙醇沉淀2-4小时后过滤,真空浓缩至比重为1.3的浓缩液,保存待用;
(7)将60-70%步骤3的浓缩液和30-40%步骤6的浓缩液倒入配料罐中混合,加入填充剂和湿滑剂后搅拌均匀,浓缩成稠糊状并制成软材;将软材过18目筛网进行造粒,然后在50-60℃条件下干燥,所得颗粒进行压片,得到清咽利喉苦丁茶含片。
4.根据权利要求3所述的具有降三高作用的苦丁茶含片的生产方法,其特征在于:所述的乙醇沉淀是将质量分数为80-90%的乙醇加入浓缩液中,边搅拌边缓慢添加,调至浓缩液中醇含量为40-70%时密闭2-4小时再过滤。
5.根据权利要求3所述的具有降三高作用的苦丁茶含片的生产方法,其特征在于:所述的填充剂为糊精、微晶纤维素、变性淀粉、预胶化淀粉、木糖醇,羧甲基淀粉钠中的一种或几种。
6.根据权利要求3所述的具有降三高作用的苦丁茶含片的生产方法,其特征在于:所述的湿滑剂为硬脂酸盐、滑石粉、氢化物植物油、聚乙二醇中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410722040.7A CN104474472B (zh) | 2014-12-03 | 2014-12-03 | 具有降三高作用的苦丁茶含片及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410722040.7A CN104474472B (zh) | 2014-12-03 | 2014-12-03 | 具有降三高作用的苦丁茶含片及其生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104474472A true CN104474472A (zh) | 2015-04-01 |
CN104474472B CN104474472B (zh) | 2018-04-10 |
Family
ID=52749173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410722040.7A Expired - Fee Related CN104474472B (zh) | 2014-12-03 | 2014-12-03 | 具有降三高作用的苦丁茶含片及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104474472B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055901A (zh) * | 2015-07-30 | 2015-11-18 | 广西健宝石斛有限责任公司 | 一种含铁皮石斛的胶囊及其制备方法 |
CN106722992A (zh) * | 2016-12-20 | 2017-05-31 | 钦州市星火计划办公室 | 一种柿子含片及其制备方法 |
CN107669984A (zh) * | 2017-11-01 | 2018-02-09 | 李西平 | 一种用于治疗高血脂的组合物及其固体饮料和制备方法 |
JP2021138647A (ja) * | 2020-03-04 | 2021-09-16 | 株式会社栄進製薬 | 血糖値上昇抑制剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199996A (ja) * | 2000-01-24 | 2001-07-24 | Pola Chem Ind Inc | アシルCoAコレステリルアシルトランスフェラーゼ阻害剤及びそれを含有してなる高脂血症用の組成物 |
CN1370593A (zh) * | 2002-02-08 | 2002-09-25 | 赵宝忠 | 苦丁含片 |
CN104082480A (zh) * | 2014-06-19 | 2014-10-08 | 谭卓勇 | 无糖桔梗茶饮料及其制备方法 |
-
2014
- 2014-12-03 CN CN201410722040.7A patent/CN104474472B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199996A (ja) * | 2000-01-24 | 2001-07-24 | Pola Chem Ind Inc | アシルCoAコレステリルアシルトランスフェラーゼ阻害剤及びそれを含有してなる高脂血症用の組成物 |
CN1370593A (zh) * | 2002-02-08 | 2002-09-25 | 赵宝忠 | 苦丁含片 |
CN104082480A (zh) * | 2014-06-19 | 2014-10-08 | 谭卓勇 | 无糖桔梗茶饮料及其制备方法 |
Non-Patent Citations (5)
Title |
---|
IAPS: "降血脂秘方", 《HTTP://WWW.360DOC.COM/CONTENT/12/0711/07/7820845_223502113.SHTML》 * |
朱成全等: "《防治‘四高’药膳大全》", 28 February 2014, 中国医药科技出版社 * |
李秀才: "《糖尿病的中医治疗》", 30 November 2007, 科学技术文献出版社 * |
杨卫平等: "《新编中草药图谱及经典配方2》", 31 May 2014, 贵州科技出版社 * |
林寿宁等: "《慢性胃炎、消化性溃疡中医防治与调养》", 28 February 2010, 化学工业出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055901A (zh) * | 2015-07-30 | 2015-11-18 | 广西健宝石斛有限责任公司 | 一种含铁皮石斛的胶囊及其制备方法 |
CN106722992A (zh) * | 2016-12-20 | 2017-05-31 | 钦州市星火计划办公室 | 一种柿子含片及其制备方法 |
CN107669984A (zh) * | 2017-11-01 | 2018-02-09 | 李西平 | 一种用于治疗高血脂的组合物及其固体饮料和制备方法 |
JP2021138647A (ja) * | 2020-03-04 | 2021-09-16 | 株式会社栄進製薬 | 血糖値上昇抑制剤 |
JP7090267B2 (ja) | 2020-03-04 | 2022-06-24 | 株式会社栄進製薬 | 血糖値上昇抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
CN104474472B (zh) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN101632769B (zh) | 一种调节血糖的中药组合物及其制备方法 | |
CN103041118A (zh) | 一种具有降血糖降血脂作用的组合物 | |
CN103168883A (zh) | 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法 | |
CN103749822A (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
CN103223111B (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
CN107412665B (zh) | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 | |
CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
CN104013845B (zh) | 一种降血糖中药制剂及制备方法 | |
CN104474472B (zh) | 具有降三高作用的苦丁茶含片及其生产方法 | |
CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
CN102885975A (zh) | 一种治疗糖尿病的中药组合物 | |
CN103041070B (zh) | 一种银杏叶降脂降压保健品及其制备方法 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN103749819A (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
CN104586977A (zh) | 苦丁茶颗粒剂及其生产方法 | |
CN105535416A (zh) | 一种治疗甲状腺结节的药物及制作方法 | |
CN103690811A (zh) | 一种降血压、预防头昏眼花的中药口服液及其制备方法 | |
CN104383232B (zh) | 清热解毒苦丁茶含片及其生产方法 | |
CN104027652B (zh) | 一种降血糖中药制剂及其制备方法 | |
CN102949681B (zh) | 一种预防或治疗感冒的组合物及其制备方法 | |
CN105169149A (zh) | 一种治疗痰火瘀结型甲状腺癌的中药组合物及制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Huanming Inventor before: Li Youjun |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180410 Termination date: 20201203 |
|
CF01 | Termination of patent right due to non-payment of annual fee |